A Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Effectiveness of Isatuximab in Patients Awaiting Kidney Transplantation

Overview

Información sobre este estudio

The primary purpose of this study in Phase 1 is to characterize the safety and tolerability of isatuximab in kidney transplant candidates.  The primary purpose of this study in Phase 2 is to evaluate the effectiveness of isatuximab in desensitization of patients awaiting kidney transplantation.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Diagnosis of chronic kidney disease (CKD) and active candidate on the kidney donor waitlist at the time of screening.
  • Body mass index (BMI) ≤ 40 kg/m^2.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent.

For Participants in Cohort A

  • Active candidates on the kidney waitlist with living donor.

For Participants in Cohort B

  • Active candidates on the kidney waitlist with no living donor cleared for donation.

Exclusion Criteria:

  • Significant cardiac dysfunction.
  • Known active, recurrent, or chronic infection.
  • Active lupus or uncontrolled diabetes.
  • Prior treatment with rituximab within 6 months from SAR650984 administration.
  • Inadequate organ and bone marrow function at screening.
  • Pregnant or breastfeeding women or women who intend to become pregnant during participation in the study.
  • Known intolerance or hypersensitivity to any component of SAR650984 or premedications.
  • Participants who are not suitable for participation as judged by the Investigator.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Mark Stegall, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20502017

Mayo Clinic Footer